Because, unlike breast cancer, the HER2 (ERBB2) gene is rarely amplified in PCa, investigators have proposed that effective HER2 based therapies in PCa will depend on patient selection and / or combination therapies with agents targeting other EGF receptor family molecules or additional molecular targets [31]. The gene discussed is ERBB2; the disease is breast carcinoma.